Charts

Gainers Cue Health (NASDAQ:HLTH) shares increased by 12.1% to $0.22 during Friday's after-market session. The company's market cap ...

Shares of Jabil Inc. (NYSE: JBL) fell sharply during Friday’s session after the company reported financial second-quarter results ...

Gainers Better Therapeutics (NASDAQ:BTTX) shares increased by 65.4% to $0.06 during Friday's regular session. The market value of their ...

U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 100 points on Friday. Following the market opening ...

Gainers Better Therapeutics (NASDAQ:BTTX) shares increased by 85.4% to $0.06 during Friday's pre-market session. The market value of ...

Shares of Cardlytics, Inc. (NASDAQ: CDLX) rose sharply in today’s pre-market trading after the company reported ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's time to start the final day of trading this week with a look into the biggest pre-market stock movers for Friday morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow traded ...

Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter ...

Gainers Psyence Biomedical (NASDAQ:PBM) shares rose 52.9% to $1.59 during Thursday's regular session. The company's market cap stands ...

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow traded ...

Better Therapeutics, Inc. (NASDAQ: BTTX) (the “Company”) announced today that the Company is terminating its employees and will explore strategic alternatives, including assignment for the benefit of creditors and/or a wind-down of the Company. This decision was made at a special meeting of the board of directors on Wednesday evening, March 13, 2024. Further, as previously disclosed, the Company’s securities are subject to delisting from the Nasdaq Stock Market unless the Company presents a plan to regain compliance with Nasdaq’s continued listing standards before the Nasdaq hearings panel. The Company has voluntarily requested a delisting of its securities and expects its securities to be delisted in the near term.

Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced a major partnership with the American College of Lifestyle Medicine’s (ACLM) National Training Initiative (NTI), aimed at improving diabetes outcomes in underserved communities across the United States. Through this partnership, Better Therapeutics is committed to making one million prescriptions of its U.S. Food and Drug Administration (FDA)-authorized product, AspyreRx, available to support underserved patients through 1,400 Federally Qualified Health Center (FQHC) organizations.

Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced the acceptance of a late-breaking abstract presenting 180-day outcomes data and its participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), to be held from March 6 to 9, 2024, in Florence, Italy. ATTD serves as a premier international forum showcasing cutting-edge advancements in diabetes care, bringing together clinicians, researchers, industry leaders, and policymakers from around the world to exchange knowledge and foster collaboration in the pursuit of innovative solutions for diabetes management.

SAN FRANCISCO, March 04, 2024--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced the acceptance of a late-breaking abstract presenting 180-day outcomes data and its participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), to be held from March 6 to 9, 2024, in Florence, Italy. ATTD serves as a premier international forum showcasing c

ORLANDO, FL / ACCESSWIRE / March 1, 2024 / RedChip Companies will air interviews with Better Therapeutics, Inc. (Nasdaq:BTTX) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this ...

Shares of Fluor Corporation (NYSE: FLR) fell during Tuesday’s session following fourth-quarter results. Fluor posted adjusted ...

Gainers Monopar Therapeutics (NASDAQ:MNPR) shares rose 138.8% to $0.82 during Tuesday's regular session. The market value of their ...

Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its novel Cognitive Behavioral Therapy (CBT) platform intended to treat adults with metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH. Breakthrough status is reserved for technologies that demonstrate the potential to be more effective than current standard of care in patients with serious or life-threatening conditions.

Gainers BioSig Technologies (NASDAQ:BSGM) stock increased by 7.7% to $0.96 during Monday's after-market session. The company's market ...

Better Therapeutics Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced that it has entered into a rebate agreement with one of the nation’s leading Pharmacy Benefit Managers (PBMs) negotiating on behalf of over 70 million lives in the US. The rebate agreement, effective January 1, 2024, applies to the PBM’s commercial book of business and provides plan participants of the PBM the ability to add AspyreRx™ to their formularies with rebate eligibility.

Investors who take an interest in Better Therapeutics, Inc. ( NASDAQ:BTTX ) should definitely note that the Co-Founder...

Better Therapeutics Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced the publication of health economic data for its prescription-only digital behavioral treatment for type 2 diabetes (T2D), AspyreRx. The study, titled "Cost-Effectiveness Analysis of a Prescription Digital Therapeutic in Type 2 Diabetes'' has been published in Advances in Therapy, a prominent peer-reviewed medical journal.

Gainers Atreca (NASDAQ:BCEL) stock moved upwards by 63.4% to $0.17 during Thursday's pre-market session. The market value of their ...

Better Therapeutics Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, and Glooko, Inc., a global leader in chronic condition management, today announced a partnership to integrate Better Therapeutics’ AspyreRx™ digital behavioral treatment for type 2 diabetes (T2D) into Glooko’s diabetes management platform. This collaboration will enable healthcare providers in the United States who use the Glooko platform to identify suitable patients for AspyreRx, facilitate prescriptions, and track patients throughout their treatment.

Multiple insiders secured a larger position in Better Therapeutics, Inc. ( NASDAQ:BTTX ) shares over the last 12...

Shares of LumiraDx Limited (NASDAQ: LMDX) fell sharply in pre-market trading after the company agreed to sell its point-of-care ...

Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced it has submitted a request to the U.S. Food and Drug Administration (FDA) for Breakthrough Device Designation for its novel PDT designed to treat metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NAFLD and NASH.

Gainers 180 Life Sciences (NASDAQ:ATNF) shares rose 38.2% to $0.47 during Tuesday's after-market session. The company's market cap ...

Gainers Avidity Biosciences (NASDAQ:RNA) shares rose 38.1% to $8.51 during Tuesday's pre-market session. The market value of their ...

Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today disclosed several initiatives aimed at extending the company's cash runway sufficiently to demonstrate commercial traction with its lead product, AspyreRx. The company launched AspyreRx in October of this year, after receiving U.S. Food and Drug Administration (FDA) authorization in July for the treatment of adults with type 2 diabetes.

Shares of The Gap, Inc. (NYSE: GPS) jumped in pre-market trading after the company reported better-than-expected financial results for ...

Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced it has been awarded Frost & Sullivan’s prestigious 2023 Best Practices Technology Innovation Leadership Award in the North American diabetes digital behavioral therapeutics industry.

Better Therapeutics (NASDAQ:BTTX) reported its Q3 earnings results on Thursday, November 9, 2023 at 07:00 AM. Here's what investors need ...

Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today reported financial results for the third quarter 2023 and provided an update on progress towards achieving key corporate milestones.

Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today announced it will release its third quarter 2023 financial results before the market opens on Thursday, November 09, 2023. Management will host a conference call and webcast to provide a business update at 8:30 a.m. ET / 5:30 a.m. PT on Thursday, November 09, 2023.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum ...

Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the ...

Gainers Miromatrix Medical (NASDAQ:MIRO) shares increased by 217.2% to $3.3 during Monday's regular session. The current volume of 2.9 ...

Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced its participation in the American College of Lifestyle Medicine's (ACLM) 2023 Lifestyle Medicine Annual Conference (LM2023), to be held October 29 to November 1, 2023, in Denver, Colorado. The conference brings together medical professionals, including physicians, healthcare executives, academic faculty, and researchers from across the U.S. and around the world, and seeks to drive the transformation of healthcare by highlighting how shifting lifestyle related behaviors can treat, prevent, and often reverse chronic disease.

Gainers SeaStar Medical Holding (NASDAQ:ICU) shares rose 52.9% to $0.69 during Wednesday's regular session. Trading volume for SeaStar ...

Gainers Biocept (NASDAQ:BIOC) stock moved upwards by 48.9% to $0.76 during Wednesday's pre-market session. The company's market cap ...

Gainers Better Therapeutics (NASDAQ:BTTX) stock rose 56.7% to $0.49 during Monday's pre-market session. The market value of their ...

Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced the commercial launch of AspyreRx, the first cognitive behavioral therapy (CBT) app to receive U.S Food and Drug Administration (FDA) authorization as a Class II device to treat adults with type 2 diabetes (T2D). AspyreRx is a prescription-only therapy, backed by a randomized controlled trial (RCT) that demonstrated statistically and clinically significant durable reductions in A1c at 90 and 180 days vs. the standard of care control group. The RCT also resulted in statistically significant improvements in blood pressure, weight, mood, and quality of life, as well as having lower medication utilization and fewer adverse events vs. the control group. Licensed healthcare providers are now able to prescribe AspyreRx, and the app is available for download on the Apple App and Google Play Stores.

Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced top-line findings from a recent subgroup analysis of AspyreRx (formerly BT-001) in its pivotal trial for type 2 diabetes (T2D). The analysis reveals that adjunctive use of AspyreRx with standard of care, including GLP-1 receptor agonists (GLP-1), leads to a substantially greater clinical improvement compared to control participants who did not incorporate AspyreRx into their regimen. The subgroup analysis, involving approximately 160 participants on GLP-1s randomized to the active and control arm of the study, exhibited an average reduction in HbA1c of 0.7% at 90 days, between the two groups. This exceeds the results of the entire BT-001 pivotal trial population, where AspyreRx outperformed the standard of care control arm by 0.4%. Both reductions were statistically significant when compared to the corresponding control group.

Gainers Maris-Tech Ltd. (NASDAQ: MTEK) shares rose 38% to $1.38 in pre-market trading, after gaining 6% on Friday. Maris-Tech, on ...

Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced the pre-print publication of the LivVita study's results in Gastro Hep Advances, a peer reviewed journal produced by the American Gastroenterological Association (AGA). The study successfully met its primary endpoint by reducing liver fat within 90 days, while also achieving key secondary endpoints related to improved liver health without any device related adverse events. The company anticipates submitting a request to the FDA for Breakthrough Device Designation by the end of 2023.

Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired ...

Gainers RVL Pharmaceuticals plc (NASDAQ: RVLP) shares rose 181.8% to $0.2201 in pre-market trading. Novo Integrated Sciences, ...

Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced it has completed the enrollment of 1,000 participants across two studies as part of its ongoing clinical program to evaluate the long-term effectiveness of AspyreRxTM (formerly BT-001). AspyreRx received FDA authorization in July 2023 as the first PDT to deliver Cognitive Behavioral Therapy (CBT) to treat adults with type 2 diabetes (T2D).